Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Comparing CAR T-Cell Therapies for R/R Multiple Myeloma
Comparing CAR T-Cell Therapies for R/R Multiple Myeloma
Project Oncology®
Comparing CAR T-Cell Therapies for R/R Multiple Myeloma
Charles Turck, PharmD, BCPS, BCCCP; Krina Patel, MD, MSc
- Charles Turck, PharmD, BCPS, BCCCP
- Krina Patel, MD, MSc
Updated Overall Survival From Stage 1 of PRESERVE-003: Gotistobart vs Docetaxel in Metastatic Squamous NSCLC After Anti-PD-(L)1 Progression
Updated Overall Survival From Stage 1 of PRESERVE-003: Gotistobart vs Docetaxel in Metastatic Squamous NSCLC After Anti-PD-(L)1 Progression
Oncology and Hematology
Updated Overall Survival From Stage 1 of PRESERVE-003: Gotistobart vs Docetaxel in Metastatic Squamous NSCLC After Anti-PD-(L)1 Progression
Byoung Chul Cho, MD, PhD
- Byoung Chul Cho, MD, PhD
Integrating Molecular Testing into NSCLC Care
Integrating Molecular Testing into NSCLC Care
Project Oncology®
Integrating Molecular Testing into NSCLC Care
Geoffrey Oxnard, MD
- Geoffrey Oxnard, MD
Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Project Oncology®
Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Laura Alder, MD
- Laura Alder, MD
The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
Project Oncology®
The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
Raghava Reddy Induru, MD
- Raghava Reddy Induru, MD
Improving Adherence and Toxicity Monitoring in NSCLC Care
Improving Adherence and Toxicity Monitoring in NSCLC Care
Project Oncology®
Improving Adherence and Toxicity Monitoring in NSCLC Care
Raghava Reddy Induru, MD
- Raghava Reddy Induru, MD
The Importance of Multidisciplinary Coordination in NSCLC Care
The Importance of Multidisciplinary Coordination in NSCLC Care
Project Oncology®
The Importance of Multidisciplinary Coordination in NSCLC Care
Laura Alder, MD
- Laura Alder, MD
Key Questions Shaping Antibody-Drug Conjugate Use in NSCLC
Key Questions Shaping Antibody-Drug Conjugate Use in NSCLC
Project Oncology®
Key Questions Shaping Antibody-Drug Conjugate Use in NSCLC
Laura Alder, MD
- Laura Alder, MD

Medical News

Medical News
Medicare Part D Anticancer Drug Appeals Overturned 1 in 5 Times
09/28/2026
Read more
Medical News
Stepped Reminders Boost Lung Cancer Screening Adherence
09/17/2026
Read more
Medical News
Blood mRNA Panel May Detect Early Pancreatic Cancer
09/17/2026
Read more
Medical News
AI Tracks Colorectal Liver Metastases on Follow-up CT
09/17/2026
Read more

CME/CE

Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
MinuteCE®
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
0.50 program credits
- Komal Jhaveri, MD, FACP
0.50 program credits
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
MinuteCE®
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 program credits
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
MinuteCE®
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Virginia Kaklamani, MD, DSc
0.50 program credits
- Virginia Kaklamani, MD, DSc
0.50 program credits
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
MinuteCE®
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Natalie S. Callander, MD
0.75 program credits
- Natalie S. Callander, MD
0.75 program credits

Clinical Practice

CAR T-Cell vs Bispecific Therapies for R/R Multiple Myeloma: How They Compare
CAR T-Cell vs Bispecific Therapies for R/R Multiple Myeloma: How They Compare
Project Oncology®
CAR T-Cell vs Bispecific Therapies for R/R Multiple Myeloma: How They Compare
Charles Turck, PharmD, BCPS, BCCCP; Krina Patel, MD, MSc
- Charles Turck, PharmD, BCPS, BCCCP
- Krina Patel, MD, MSc
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Project Oncology®
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Alexandria May, PharmD, BCPS; Shannon Raber, MS, CPNP, RN
- Alexandria May, PharmD, BCPS
- Shannon Raber, MS, CPNP, RN
- Bridget Archambault, MSN, CPNP
A Patient-First Approach to Smoking Cessation and Lung Cancer Screening
A Patient-First Approach to Smoking Cessation and Lung Cancer Screening
Project Oncology®
A Patient-First Approach to Smoking Cessation and Lung Cancer Screening
Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
- Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
A New Era of Hope in Non-Small Cell Lung Cancer Care
A New Era of Hope in Non-Small Cell Lung Cancer Care
Project Oncology®
A New Era of Hope in Non-Small Cell Lung Cancer Care
Geoffrey Oxnard, MD
- Geoffrey Oxnard, MD

Programs

Tobacco-Related Stigma as a Barrier to Lung Cancer Screening
Tobacco-Related Stigma as a Barrier to Lung Cancer Screening
Project Oncology®
Tobacco-Related Stigma as a Barrier to Lung Cancer Screening
Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
- Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Project Oncology®
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Geoffrey Oxnard, MD
- Geoffrey Oxnard, MD
Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
Project Oncology®
Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
Christine Bestvina, MD
- Christine Bestvina, MD
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
CME/CE Virtual Event
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
September 29, 2026
12:00 PM - 01:00 PM EDT
1.00 credit